Study of Circulating Tumor DNA in Adults with Colorectal Cancer Undergoing Surgery to Remove Liver Metastases

What this Trial Is About

Researchers are evaluating the prognostic value of circulating tumor DNA ctDNA as a biomarker to predict disease response, recurrence, or death in patients undergoing surgery to remove colorectal cancer liver metastases. This prospective multicenter cohort study focuses on patients with colorectal adenocarcinoma who are eligible for curative-intent liver surgery. The goal is to better understand how ctDNA levels relate to patient outcomes after surgery. Participants will have blood collected at specific times based on their clinical situation, including standard surgery, combined surgery, reverse strategy, or two-stage hepatectomy approaches. The study observes patients undergoing curative surgical resection of isolated colorectal liver metastases considered resectable or potentially resectable by a multidisciplinary team. No experimental drugs or treatments are administered as this is an observational study. During the study, researchers will monitor disease-free survival up to 36 months after surgery and collect data on event-free survival, overall survival, time to surgical failure, and the prognostic value of ctDNA for up to 4 years. Assessments include clinical evaluations and blood sample collections to correlate ctDNA with outcomes and clinical features. Participants will be followed regularly to track these measures, with the total study duration lasting several years to observe long-term outcomes.

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases